http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2371146-C1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c9e08e51f7fdfb77bf78451526ab3442
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-00
filingDate 2008-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2009-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f07a731097f4f1b1c348e09e10dcf178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84a5a7ea7fd675125f2e55ef7e57c298
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0294d3556d5a7354f91277e3841b31b0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f062cb46f5a7c6b2b93ad43f178cbc3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51ae2df8e50dcd93869664d3e712031d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40468c07ad76ae5bc8abaf60d746589d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44602626dd4b652483afb359d56fe452
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea0ef5ce07a1fa6c1cdb2cbae5c56ae2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23b3f9ce353f4e2f35296fc2b77f4fbd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_215c9537c9c1813050e65f56a3368d36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dedae337fe1d10333df88ab48846ec7e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37f3d21a4266566bd3a1161aa1b1376c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7fc03b2b9cce62fff65d621ad5d9e441
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6767332322f9e985f2a34f228ea245e4
publicationDate 2009-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2371146-C1
titleOfInvention Method for treating progressive myopia combined with extraocular pathology in form of inflammatory kidney diseases in children
abstract FIELD: medicine. n SUBSTANCE: invention relates to medicine, namely to ophthalmology and paediatrics. Drug therapy of inflammatory kidney diseases is carried out. In addition, head region is exposed to pulse low-frequency electromagnetic field distantly through a radiator being from the patient's eyes at 20-30 cm, within 10 days. Pulse repetition rate varies daily as 40-60-80-60-40-60-80-60-40-60 Hz. n EFFECT: method allows for treatment of myopia combined with extraocular pathology in the form of inflammatory kidney diseases in children. n 2 ex
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2494708-C1
priorityDate 2008-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5742673
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4831
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448619652
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419503509
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23665637
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419591374
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426120905
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419503345
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID37768
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5562578

Total number of triples: 35.